The rich generally run conservative on investments. An OTC stock is always considered high risk, so Klump might be loathe to recommend it to friends. Which is why you don't see Argonne in the game.

However Klump himself owns over 12 million shares so you can't say he doesn't have skin in the game. You and I may say if he buys more shares the greater the reward. But we don't know his liquidity or how he balances risk/reward.

So how best to raise capital? A new offering and massive dilution is bad news. More convertible notes will only lead to more share dumping which is already a problem. A straight loan? The interest would be usurious and a call on the loan could lead to bankruptcy.

The least risk is a TO and lowering costs until FDA approval and revenue. Which is what we are doing and would amply explain quite a few delays.